Highest-materiality recent filing
Actinium gets NYSE plan acceptance through Nov 2027; adds Actimab-A patents and manufacturing
NYSE Regulation accepted compliance plan; listing extended through Nov 27, 2027, maximum period under Section 1009.
Actinium submits NYSE American compliance plan after equity deficiency notice
Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.
Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
FDA requires additional Phase 3 trial for Iomab-B; SIERRA alone not adequate for BLA filing
SIERRA met primary endpoint (dCR) with p<0.0001, but FDA now demands overall survival benefit in randomized head-to-head trial.
Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML
Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).
Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)
Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.
Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones
Upfront payment of $35 million from Immedica upon signing.
Actinium appoints Swaminathan as Chief Business Officer, Desai as CMO; Berger resigns
Mark Berger resigns as CMO effective Sept 24, 2021; no disagreement with company.
On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
Dr. Mark S. Berger, the Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the “Company”), notified the Company that he will be resigning effective as of September 24, 2021.
Max materiality 0.90 · Median 0.47 · Most common event other_material